Relapsed and refractory multiple myeloma (RRMM) research hub

A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA

This study is testing a new treatment called idecabtagene vicleucel for multiple myeloma. It focuses on people whose myeloma has come back or not responded to previous treatments, and some high-risk cases, to see how well it works and if it's safe.